Project Grant R43AI084212

This $3,304,164 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to determine the real-world comparative effectiveness, cost-effectiveness, safety, and impact of the recently approved maternal respiratory syncytial virus (RSV) vaccine and extended-half-life monoclonal antibody products in reducing RSV-associated respiratory morbidities in infants and...

This federal Project Grant award of $545,563.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund a study on the "Real-World Effectiveness of Maternal RSV Vaccination". The grant aims to evaluate the effectiveness of the world's first licensed RSV vaccine when administered to pregnant women between 32-36 weeks gestation, in preventing RSV-associated lower respiratory tract...

This Project Grant award of $458,250.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a VP4-based pseudovirus nanoparticle rotavirus vaccine for oral immunization. The award will fund research to create a non-replicating rotavirus vaccine candidate called S-VP4E, which consists of a calicivirus inner shell and multiple rotavirus spikes (VP4E) on the surface. This...

The U.S. Department of Agriculture (USDA) awarded a $300,000 grant under the Agriculture and Food Research Initiative (AFRI) program to Oklahoma State University (OSU) to develop a novel single-cycle vaccine against bovine respiratory syncytial virus (BRSV). The project aims to pioneer the development of two single-cycle BRSV vaccine prototypes: an 'MNull' vaccine that lacks the essential matrix protein, and a 'PRef' vaccine with a modified fusion protein. OSU will evaluate the immunogenicity...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research to comprehensively study the antibody response to novel respiratory syncytial virus (RSV) vaccines in a national observational cohort of immunosuppressed persons (ISPs). The $775,187 award to The Johns Hopkins University aims to better understand the impact of immunosuppression on antibody generation and...

This Project Grant award of $364,484, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel bronchodilators to alleviate respiratory distress in young children infected with Respiratory Syncytial Virus (RSV). The awardee, The General Hospital Corporation (doing business as Massachusetts General Hospital), will screen 8 clinically relevant soluble guanylate cyclase (SGC)...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $306,347 to Sunflower Therapeutics PBC to develop a first-in-class automated, continuous cell disruption method integrated with a continuous cell culturing bioreactor platform for virus-like particle (VLP) vaccine manufacturing. The goal is to simplify the VLP vaccine manufacturing process to lower the cost of goods manufactured (COGM) and...

The federal Cooperative Agreement award U19AI181984, totaling $44,108,652.00, was granted by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of this 3-year award is to develop vaccines and antibody-based treatments for viruses in the Paramyxoviridae, Peribunyaviridae, and Phleboviridae families, with a focus on prototype viruses such as human parainfluenza virus 3 (HPIV3), Oropouche virus...

This Project Grant award of $565,834 from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the long-term impact of early-life respiratory syncytial virus (RSV) infection on the development of childhood asthma. The research will focus on understanding how RSV infection can cause epigenetic modifications in lung epithelial cells that lead to persistent changes in the lung's...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,013,468 to Inhalon Biopharma, Inc. to advance the development of IN-003PI, a passive immunization treatment against human metapneumovirus (MPV) infections. The funding will support key research activities such as producing GLP-compliant antibody batches, conducting IND-enabling toxicology and efficacy studies, and...